Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September

Kura Oncology, Inc. (NASDAQ:KURA) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 10,190,000 shares, a decrease of 5.2% from the September 15th total of 10,750,000 shares. Currently, 15.7% of the company’s shares are short sold. Based on an average daily volume of 577,600 shares, the days-to-cover ratio is currently 17.6 days.

Analyst Ratings Changes

KURA has been the topic of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Friday, August 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their target price for the company from $26.00 to $19.00 in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.20.

Kura Oncology Stock Performance

KURA opened at $18.27 on Thursday. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average price is $19.56 and its two-hundred day moving average price is $20.25. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -8.42 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter last year, the company posted ($0.53) EPS. Kura Oncology’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts expect that Kura Oncology will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in Kura Oncology during the third quarter worth $25,000. Quarry LP bought a new stake in shares of Kura Oncology in the 2nd quarter worth $196,000. Alethea Capital Management LLC grew its stake in shares of Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock worth $5,475,000 after acquiring an additional 6,300 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after acquiring an additional 58,422 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.